Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click here to see it on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

Click on thumbnail to view the full-size ad on AdPharm

My goal is to breathe better very day.

Once-daily Spiriva helps people with COPD breathe better.

There may be more you can do to help manage your COPD.
Talk yo your doctor about lifestyle changes and Spiriva.
Also call 1.877.Spiriva (774.7482) or visit Spiriva.com

Brand name: Spiriva
Generic name/category: Tiotropium (Bronchodilators, Muscarinic antagonists, Thiophenes, Epoxides)
Company: Pfizer and Boehringer Ingelheim
Country/Market: USA, North America
Indication(s)/use: chronic obstructive pulmonary disease (COPD)
Target: Consumers (DTC)
Tagline: Once-daily Spiriva helps people with COPD breathe better
Medium: Print ad
Size/duration: single-page
Publication/Aired: USA News & World Report – October 2009

To see all of this brand’s ads on AdPharm, click here

Click on thumbnail to view the full-size ad on AdPharm

Rebif New formulation
Balancing performance & Safety

Brand name: Rebif
Generic name/category: Interferon beta-1a, Cytokines, Immunostimulants
Company: Merck Serono
Country/Market: UK, Europe
Indication(s)/use: Multiple Sclerosis (MS)
Target: Healthcare Professionals (HCP)
Tagline: A balanced choice in MS
Medium: Print ad
Size/duration: single-page
Publication/Aired: 2009

To see all of this brand’s ads on AdPharm, click here

nowosc -
rewolucja w walce z nadwaga
New -
A revolution in the fight against weight

Orlistat (marketed as a prescription under the trade name Xenical by Roche or over-the-counter as Alli by GlaxoSmithKline), also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to simplicity and stability, orlistat rather than lipstatin was developed into an anti-obesity drug.

The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggests that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.

More on Wikipedia

Brand name: Alli
Generic name/category: Orlistat, Antiobesity drugs, Lactones
Company: GlaxoSmithKline Consumer Healthcare (GSK)
Country/Market: Poland, Europe
Indication(s)/use: obesity
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: single-page
Publication/Aired: Gazeta Farmaceutyczna – September 2009

To see all of this brand’s ads on AdPharm, click here

Alli, nueva solución para ayudarte a perder un 50% más de peso.
Alli, a new solution to help you lose 50% more weight.

Orlistat (marketed as a prescription under the trade name Xenical by Roche or over-the-counter as Alli by GlaxoSmithKline), also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to simplicity and stability, orlistat rather than lipstatin was developed into an anti-obesity drug.

The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggests that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.

More on Wikipedia

Brand name: Alli
Generic name/category: Orlistat, Antiobesity drugs, Lactones
Company: GlaxoSmithKline Consumer Healthcare (GSK)
Country/Market: Spain, Europe
Indication(s)/use: obesity
Target: Consumers (DTC)
Medium: Print ad
Size/duration: single-page
Publication/Aired: Psychologies – August 2009

To see all of this brand’s ads on AdPharm, click here

New indication
A new reason to treat with Revatio…

Revatio delays clinical worsening in patients with PAH (WHO Group I)

Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was developed and is being marketed by the pharmaceutical company Pfizer. It acts by inhibiting cGMP specific phosphodiesterase type 5, an enzyme that regulates blood flow in the penis. Since becoming available in 1998, sildenafil has been the prime treatment for erectile dysfunction; its primary competitors on the market are tadalafil (Cialis) and vardenafil (Levitra).

As well as erectile dysfunction, sildenafil citrate is also effective in the rare disease pulmonary arterial hypertension (PAH). It relaxes the arterial wall, leading to decreased pulmonary arterial resistance and pressure. This in turn reduces the workload of the right ventricle of the heart and improves symptoms of right-sided heart failure. Because PDE-5 is primarily distributed within the arterial wall smooth muscle of the lungs and penis, sildenafil acts selectively in both these areas without inducing vasodilation in other areas of the body. Pfizer submitted an additional registration for sildenafil to the FDA, and sildenafil was approved for this indication in June 2005. The preparation is named Revatio, to avoid confusion with Viagra, and the 20 milligram tablets are white and round. Sildenafil joins bosentan and prostacyclin-based therapies for this condition.

More on Wikipedia

Brand name: Revatio
Generic name/category: Sildenafil, PDE5 inhibitors, Citrates
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: Pulmonary Arterial Hypertension (PAH)
Target: Healthcare Professionals (HCP)
Tagline: Start with confidence
Medium: Print ad
Size/duration: three-page spread
Publication/Aired: Chest – August 2009